New technology enables the insertion of a large segment of DNA into a genome, potentially expanding gene therapy treatment ...
Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...
That is because scientists keen to achieve more precise control over an organism’s genetics are experimenting with a ...
Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to ...
Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...
Topline results from the pivotal HAELO trial demonstrate that a single infusion of lonvo-z significantly reduces HAE attacks and the need for chronic prophylactic therapy.
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and ...
5don MSN
Re-engineered human cells boost gene-editing particle potency across multiple delivery systems
Gene editing has emerged as a powerful approach for targeting the genetic causes of disease, but getting the editing ...
Profluent and Lilly teamed up on AI‑designed enzymes in a deal worth up to $2.25B. Big tech, bigger gene edits.
Intellia Therapeutics Inc. said its gene-editing treatment for a rare swelling disorder met its goal in a late-stage trial, ...
Researchers from Wageningen University & Research and Van Andel Institute used a variant of CRISPR, a gene-editing tool, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results